Hospital Infection Therapeutics Market Expected to Reach USD 3.62 Billion Globally in 2020

According to a new market report published by Transparency Market Research “Hospital Infection Therapeutics Market - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020” the hospital infection therapeutics market was valued at USD 3.06 billion in 2013 and is expected to grow at a CAGR of 3.1% from 2014 to 2020, to reach an estimated value of USD 3.62 billion in 2020.

Hospital infections, commonly known as hospital-acquired infections (HAIs) or nosocomial infections, are referred to infections that develop in patients undergoing treatment in a healthcare setting such as hospitals, nursing homes, outpatient surgery centers, dialysis centers and rehabilitation centers. According to the World Health Organization (WHO), hospital infections are those infections that occur within 48 hours of hospitalization or after 72 hours of discharge from hospitals or within 30 days after treatment. Hospital infections mostly originate in intensive care units (ICUs) of a hospital compared to other divisions. According to the Centers for Disease Control and Prevention (CDC), more than 1.7 million hospital infections from different pathogenic microorganisms combined have been reported in 2011, in the U.S. CDC also estimated that hospital infections accounted for 99,000 deaths in the U.S. in the year 2011.

We are currently offering a flat 15% discount on all purchases until end of the March 2015:-

http://www.transparencymarketresearch.com/hospital-infection-therapeutics.html

Major hospital infection therapeutics that are available in the global market has been categorized into three major drug segments, namely, antibacterial, antiviral and antifungal drugs. Some of the major types of hospital infections include hospital-acquired pneumonia, urinary tract infections, gastrointestinal disorders, bloodstream infections, surgical site infections and other hospital infections. Major driving factors for the growth of the hospital infection therapeutics market include increasing prevalence of various hospital infections, aging population, increasing healthcare awareness and demand for improved therapeutic drugs. However, increasing multi-drug resistance that has rendered many drugs obsolete and increasing number of surveillance and infection control programs, such as, point prevalence survey by ECDC, Europe and HAI prevalence survey by CDC, U.S., may restrain the growth of this market. But, increasing multi-drug resistance and demand for improved infection treatment drugs have induced various drug developers and manufacturers to develop advanced therapeutic drugs. Several drugs that are in their phase III clinical trials will soon be commercialized during the forecast period and will add to the growth of this market in future. Some of the major drugs that are in their late stage clinical trials are Ceftolozane/Tazobactam, Dalvance, Delafloxacin, MK-3415A, Surotomycin, Eravacycline, and Tedizolid among others.

North America dominates the global hospital infection therapeutics market, in terms of revenue, followed by the European market in 2013. Major factors responsible for the leading position of the North American market are high prevalence of various hospital infections, rising number of multidrug-resistant microbial pathogens, and increasing demand for advanced therapeutics. High awareness level along with high purchasing capacity of the people is also contributing to the growth of the market in the region. Rising geriatric population in North America and Europe will add to the population of affected patients with hospital infections as aged patients exhibit lowered immunity levels. Thus, the increase in affected patient population will require increased use of various therapeutic drugs, which in turn will contribute towards the growth of this market. Asia-Pacific is expected to show the highest rate of growth in the global hospital infection therapeutics market during the forecast period 2014 to 2020. Some of the major factors responsible for high growth rate are rapidly increasing prevalence of hospital-acquired infections in the region, rising awareness and demand for new and improved hospital infection treatment drugs, and increasing healthcare infrastructure as well as purchasing power of people in the region.

Actavis plc, AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Cubist Pharmaceuticals, Inc., GlaxoSmithKline plc, Johnson & Johnson Services, Inc., Merck & Co., Inc., Pfizer, Inc., and Sanofi are some of the major players operating in the global hospital infection therapeutics market.

Get Sample Report Copy with TOC and Market Research :- http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1280

See More Articles :- https://www.linkedin.com/today/author/349336221

The global hospital infection therapeutics market is segmented as follows:

Hospital Infection Therapeutics Market, by Drug Type

• Antibacterial Drugs
• Antiviral Drugs
• Antifungal Drugs

Hospital Infection Therapeutics Market, by Major Infections

• Hospital-Acquired Pneumonia
• Surgical Site Infections
• Urinary Tract Infections
• Gastrointestinal Disorders
• Bloodstream Infections
• Other Hospital Infections

Hospital Infection Therapeutics Market, by Geography

• North America
• Europe
• Asia-Pacific
• Rest of the World (RoW)

Browse Full Press Release of This Report:- http://www.transparencymarketresearch.com/pressrelease/hospital-infection-therapeutics.htm